Novartis Weighs Synergies, Spending And Tax Under Sandoz Review

‘We Believe The Generics Market Is Attractive,’ Novartis Says

 
• By Dean Rudge
  
Novartis picture
Novartis is set to complete the review by the end of 2022 • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Business

More from Generics Bulletin